1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Nextbiomedical Co. Ltd.

Nextbiomedical Co. Ltd.

KKRX:389650
27,200.00
KRW
+750.00
(+2.84%)
28.40EPS
1,457.81P/E
339.64BMarket Cap
Nov 13Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
528.2
468.58
450.09
777.62
1,324.83
2,012.7
2,172.27
Basic EPS, GAAP
-5,719
-3,440
-923
-1,198
397
-38
28.4
Free Cash Flow per Basic Share
-945.1
-1,275.25
-1,368.46
-672.87
-227.68
-232.28
-22
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4,883.31
634.82
-31.7
-736.88
5,588.37
5,863.93
5,992.63
Tangible Book Value per Share
-4,919.4
598.77
-59.44
-764.06
5,545.78
5,826.06
5,951.89
Basic Weighted Avg Shares
4
5
6
6
7
8
8
Sales/Revenue/Turnover
2,261
2,267
2,795
4,882
9,543
16,477
17,789
Operating Margin (%)
-221.36
-307.42
-206.37
-107.05
-37.46
-4.37
-12.92
Depreciation Expense
574
434
463
467
492
519
534
Net Income, GAAP
-24,477
-16,645
-5,732
-7,522
2,860
-311
233
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,082.74
-734.13
-205.07
-154.06
29.97
-1.89
1.31
Working Capital
-31,596
10,691
-13,448
-15,817
35,004
35,224
35,418
LT Debt
40
47
582
980
784
1,019
693
Total Equity
-39,106
5,084
-254
-5,901
45,191
48,107
49,163
Return on Invested Capital (%)
- -
- -
- -
- -
-11.58
- -
-4.08
Return on Capital (%)
- -
- -
- -
- -
10.94
- -
0.89
Return on Common Equity (%)
- -
- -
- -
- -
- -
-0.67
0.49

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6,693
6,591
6,260
LT Borrowings
951
774
639
LT Finance Leases
68
60
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
733,427
602,986
339,641

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
43,267
40,925
44,236
Cash, Cash Equivalents & STI
36,998
33,603
34,991
Accounts Receivable, Net
2,236
3,075
4,085
Inventories
3,036
2,870
3,059
Total Current Liabilities
8,044
8,013
8,819
Payables & Accruals
- -
- -
- -
ST Debt
6,693
6,591
6,260
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
229.46%
6.45%
Free Cash Flow
- -
-1.05%
15.95%
Net Income, GAAP
- -
-63.05%
-110.88%
Sales/Revenue/Turnover
- -
53.27%
72.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,371
2,753
2,192
2,227
9,543
2025
3,774
3,971
4,933
3,799
16,477
2026
4,121
4,936
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-56
-100
-178
17.75
397
2025
-52
-111
130.6
-6.07
-38
2026
-17.79
-77
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Don-Haeng Lee
Full Time Employees
81
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Inchon South Korea
IPO Date
Aug 20, 2024
Website
nextbiomedical.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Nextbiomedical Co. Ltd. is a South Korea-based medical device and biomaterials company that specializes in the development, manufacturing, and commercialization of therapeutic polymers and drug-device convergence solutions for minimally invasive clinical procedures. Founded in 2014 and headquartered in Incheon, South Korea, the company operates within the interventional healthcare and medical technology industry, providing advanced biomaterial platforms to hospitals, specialized surgical centers, and healthcare institutions across North America, Europe, Asia-Pacific, and domestic South Korean markets. Nextbiomedical Co. Ltd. organizes its core product offerings across therapeutic gastrointestinal and vascular intervention segments: Nexpowder, an endoscopic powder-form topical hemostatic agent engineered to transform into an adhesive hydrogel barrier upon contact with moisture for the rapid control and management of gastrointestinal bleeding; Nexsphere, spherical biocompatible microspheres designed for transcatheter arterial embolization and chemoembolization procedures targeting hypervascular tumors and arteriovenous malformations; Nexsphere-F, a fast-resorbable polymeric vascular embolization agent optimized for pain relief in musculoskeletal interventions, including chronic knee osteoarthritis and abnormal neovascular tissue embolization; and hydrogel-based tissue engineering and anti-adhesion biomaterials for post-operative surgical wound protection. The company commercializes its products through direct regional sales and multinational strategic alliances, notably maintaining a global distribution partnership with Medtronic plc for the worldwide commercialization of Nexpowder. In recent operational developments, Nextbiomedical Co. Ltd. completed its initial public offering and listed its common stock on the KOSDAQ market under ticker 389650 in August 2024, advanced clinical development and international regulatory evaluation for Nexsphere-F in the United States and Europe, and expanded its automated biomaterial production facilities in South Korea to support rising global commercial demand.